A Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults

NCT07685613 | Not Yet Recruiting

• 1 other identifier: 25NSRDM03
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to examine the effect of Magnesium Choline Citrate on cognitive function and anxiety in healthy adolescents and adults. The main questions it aims to answer are:

• What is the change in cognitive function, as assessed by the PROMIS Cognitive Function- Short Form 8a (≥18 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo?
• What is the change in cognitive function, as assessed by the Pediatric Cognitive Function - Short Form 7a (8 - 17 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? Researchers will compare Magnesium Choline Citrate with placebo to evaluate its effects on cognitive function and anxiety symptoms. Participants will be asked to:
• Consume either Magnesium Choline Citrate or placebo for 84 days
• Complete questionnaires (PROMIS Cognitive Function- Short Form 8a/Pediatric Cognitive Function - Short Form 7a, and PROMIS Emotional Distress - Anxiety - Short Form 8a/Pediatric Anxiety - Short Form 8a)
• Complete a study diary weekly

Conditions

Cognitive Function; Anxiety

Keywords

Cognitive Function; Anxiety; Magnesium Choline Citrate

Outcome Measures

Primary Outcomes (2)

• PROMIS Cognitive Function- Short Form 8a (baseline to day 84)

  Change in cognitive function, as assessed by the PROMIS Cognitive Function- Short Form 8a (≥18 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo

  Baseline (day 1) to day 84

• Pediatric Cognitive Function - Short Form 7a (baseline to day 84)

  Change in cognitive function, as assessed by the Pediatric Cognitive Function - Short Form 7a (8-17 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo

  Baseline (day 1) to day 84

Secondary Outcomes (4)

• PROMIS Cognitive Function- Short Form 8a (baseline to day 42)

  Baseline (day 1) to day 42

• Pediatric Cognitive Function - Short Form 7a (baseline to day 42)

  Baseline (day 1) to day 42

• PROMIS Emotional Distress - Anxiety - Short Form 8a (baseline to Days 42 and 84)

  Baseline (day 1) to days 42 and 84

• PROMIS Pediatric Anxiety - Short Form 8a (baseline to Days 42 and 84)

  Baseline (day 1) to days 42 and 84

Other Outcomes (1)

• Incidence of post-emergent adverse events (AE)

  Baseline (day 1) to day 84

Study Arms (2)

Magnesium Choline Citrate

EXPERIMENTAL

Dietary Supplement: Magnesium Choline Citrate

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

Magnesium Choline Citrate DIETARY_SUPPLEMENT

Participants will be instructed to take two capsules twice per day with food starting on Day 1.

Magnesium Choline Citrate

Placebo DIETARY_SUPPLEMENT

Participants will be instructed to take two capsules twice per day with food starting on Day 1

Placebo

Eligibility Criteria

• Age: 8 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females 8 years and older
• Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,
• Individuals of child-bearing potential must confirm negative baseline pregnancy status and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
• Double-barrier method
• Intrauterine devices
• Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
• Vasectomy of partner at least 6 months prior to screening
• Abstinence and agrees to use contraception if planning on becoming sexually active during the study 3. Has recently noticed a worsening in or wishes to improve one or all of the following:
• Memory
• Focus
• Attention \*Participants \<18 years of age will require parent/guardian confirmation of self-perceived worsening in or wishes to improve memory, focus or attention 4. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 5. Agrees to and self-reports ability to consume study product, and complete all questionnaires, diaries, and assessments required for participation 6. Provided voluntary, written, informed consent to participate in the study 7. Generally healthy as determined by medical history with no unstable diagnosed medical conditions

You may not qualify if:

• Individuals who self-report as pregnant, breast feeding, or planning to become pregnant during the study
• Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients
• Self-reported ongoing diagnosis of a neuropsychiatric condition and/or cognitive impairment
• Self-reported ongoing diagnosis with a stress or anxiety disorder
• Self-reported ongoing and unstable diseases/conditions in the past six months, including:
• Gastrointestinal diseases
• Hypertension
• Type I or type II diabetes
• Cardiovascular disease
• Kidney and/or liver diseases
• Thyroid condition
• Self-reported major surgery in the past 3 months or individuals who have planned surgery during the course of the study.
• Self-reported cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
• Individuals with self-reported autoimmune disease or are immune compromised
• Alcohol intake average of \>2 standard drinks per day

Sponsors & Collaborators

• Nutrisol, LLC: lead
• KGK Science Inc.: collaborator

Study Sites (1)

KGK Science Inc.

London, Ontario, N5Y 5V6, Canada

Location

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

• David Crowley

  KGK Science Inc.

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Erin Lewis, PhD

CONTACT

1-226-242-4551; elewis@kgkscience.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 29, 2026
• First Posted: July 6, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: July 6, 2026

Record last verified: 2026-06

Locations

CA (1)